Content about HCV

May 21, 2013

More evidence is emerging that interventions by pharmacists can have a profound beneficial effect on patient outcomes.

The latest example comes from Walgreens Specialty Pharmacy, which released the results of a study May 17 showing that more than two-thirds of patients with hepatitis C “achieved sustained virologic response or cure after completing newer ‘triple therapy’ treatment” backed up by a regimen of care and oversight by pharmacists, according to a Drug Store News report from senior editor Michael Johnsen.

Why the pharmacist interventions? They help improve patient compliance with the complicated drug therapy, which involves the administration of two newer protease inhibitors to prevent the HCV virus from reproducing, in combination with peginterferon and ribavirin. According to Johnsen, that powerful medicinal cocktail “significantly increased the cure rate and cut treatment time in half” for the 406 HCV patients in the study who received triple therapy with either telaprevir or boceprevir.

More evidence is emerging that interventions by pharmacists can have a profound beneficial effect on patient outcomes.

May 17, 2013

More than two-thirds of patients with hepatitis C achieved sustained virologic response or cure after completing newer “triple therapy” treatment, according to a Walgreens Specialty Pharmacy study released Friday.

DEERFIELD, Ill. — More than two-thirds of patients with hepatitis C achieved sustained virologic response or cure after completing newer “triple therapy” treatment, according to a Walgreens Specialty Pharmacy study released Friday. 

July 25, 2011

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


July 18, 2011

Walgreens is recognizing medication adherence rates as high as 96% through its hepatitis C therapy management programs across its specialty pharmacy, the pharmacy operator announced Monday.

DEERFIELD, Ill. — Walgreens is recognizing medication adherence rates as high as 96% through its hepatitis C therapy management programs across its specialty pharmacy, the pharmacy operator announced Monday.

July 6, 2011

Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

FRANKLIN LAKES, N.J. — Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

Medco said Accredo had been successful in using genotype information to identify patients who only may need 24 weeks of therapy, as opposed to 48 weeks, thus reducing costs.